RecruitingAgitationAlzheimer's Type Dementia

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Eligible age

50–90 yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Sponsor: Suven Life Sciences Limited

You may qualify if…

✓ Has a diagnosis of dementia of the Alzheimer's type according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.
✓ Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in Cognitive Disorders.
✓ Has a score between 8 and 24 (both inclusive) on Mini-Mental State Examination (MMSE).

You may not qualify if…

✕ Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, parkinson's disease, lewy body disease, frontotemporal dementia)
✕ Has symptoms of agitation that are not secondary to Alzheimer's disease (eg, pain, other psychiatric disorder, or delirium due to a metabolic disorder, systemic infection, or substance-induced).
✕ Participant (or caregiver) is deemed otherwise ineligible for participation in this study in the investigator's judgement.